BioWorld

Jan. 31, 2003

FDA Response Letter Seen As Positive Sign For MedImmune

A complete response letter from the FDA regarding FluMist has elicited a positive reaction at MedImmune Inc., which also reported record revenue as part of its fourth-quarter and year-end earnings. (BioWorld Today) Read More

Affymetrix Signs $70M GeneChip Deal With Roche Diagnostics

As West Nile Encephalitis Virus Blankets North America, Authors Seek To Disarm Immune Attacks

Corixa, GSK Changing Terms Of Cancer Vaccine Agreement

Biotech Reps Square Off With Feds Over Reimbursement Rates

Elan Continues Divestiture With Product Sales To King

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 9, 2026.

New York University identifies new analogues of mannose-6-phosphate

BioWorld Science

New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...

ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins

BioWorld

If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...